U.S. markets open in 6 hours 44 minutes
  • S&P Futures

    +22.25 (+0.51%)
  • Dow Futures

    +150.00 (+0.43%)
  • Nasdaq Futures

    +83.25 (+0.56%)
  • Russell 2000 Futures

    +18.90 (+0.85%)
  • Crude Oil

    -0.81 (-1.10%)
  • Gold

    -6.70 (-0.37%)
  • Silver

    -0.01 (-0.05%)

    -0.0006 (-0.05%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    +0.54 (+3.05%)

    -0.0001 (-0.01%)

    +0.0790 (+0.07%)

    -1,735.43 (-4.16%)
  • CMC Crypto 200

    +19.41 (+2.04%)
  • FTSE 100

    -46.12 (-0.65%)
  • Nikkei 225

    +497.43 (+1.82%)
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Merck's Antibiotic Recarbrio Gets FDA Nod for New Indication

·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Merck & Co., Inc. MRK announced that the FDA has approved the supplemental new drug application (sNDA) for its new antibacterial injection Recarbrio for a new indication. Recarbrio is now approved to treat adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible Gram-negative microorganisms.

Merck filed the sNDA seeking approval for Recarbrio to address the HABP/VABP indication in February.

The sNDA was based on the results of the pivotal phase III RESTORE-IMI 2 study. In the same, Recarbrio met both the primary and key secondary endpoints by demonstrating non-inferiority to PIP/TAZ in a 28-day all-cause mortality and clinical response at early follow-up, respectively.

Recarbrio is a fixed combination of relebactam and imipenem/cilastatin. It was approved for the treatment of adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) caused by certain susceptible gram-negative bacteria in July 2019.

Shares of Merck have declined 9.6% in the year so far compared with the industry’s decrease of 1.3%.

We note that Recarbrio received the FDA’s Qualified Infectious Disease Product (QIDP) designation for the treatment of cUTI and cIAI. QIDP is a designation granted to antibacterial or antifungal drugs for human use, intended to treat serious or life-threatening infections. This designation can boost the drug’s sales in the days ahead.

Merck’s antibacterial medicine Zerbaxa is also approved for HABP/VABP. Zerbaxa, a combination of ceftolozane and tazobactam, is also marketed for some complicated urinary tract infections.

Zacks Rank and Stocks to Consider

Merck currently has a Zacks Rank #3 (Hold). Better-ranked stocks in the large-cap pharma sector include Eli Lilly and Company LLY, AbbVie Inc. ABBV and AstraZeneca AZN. While Eli Lilly and AbbVie currently sport a Zacks Rank #1 (Strong Buy), AstraZeneca presently holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Eli Lilly’s earnings estimates have been revised 0.6% upward for 2020 and 1% for 2021 over the past 60 days. The stock has gained 13.6% year to date.

AbbVie earnings estimates have been revised 14.2% upward for 2020 and 6.6% for 2021 over the past 60 days. The stock has inched up 5.9% year to date.

AstraZeneca’s earnings estimates have moved 0.5% north for 2020 and 0.8% for 2021 over the past 60 days. The stock has rallied 8% year to date.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>

Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Merck Co., Inc. (MRK) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research